2023-505576-29-00已完成2 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors
Centessa Pharmaceuticals UK Limited1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2023年11月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
SVP, Clinical Development, Innovative Medicines
Scientific
Centessa Pharmaceuticals UK Limited
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study of MP0533 in patients with blood cancer.EUCTR2022-002432-31-NLMolecular Partners AG75
尚未招募
不适用
A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)leukemiablood cancer10024324NL-OMON53857Molecular Partners AG23
进行中（未招募）
1 期
A study of MP0533 in patients with blood cancer.relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-002432-31-LTMolecular Partners AG75
招募中
1 期
A study of MP0533 in patients with blood cancer.Relapsed/Refractory (R/R) acute myeloid leukemia (AML), Myelodysplastic Syndrome (MDS)MedDRA version: 21.1Level: PTClassification code: 10000880Term: Acute myeloid leukaemia Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864CTIS2023-505259-39-00Molecular Partners AG111
已完成
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years2023-506396-94-00Osivax48